Global Duchenne Muscular Dystrophy Drugs Market Insights, Forecast to 2025
Table of Content
1 Study Coverage
- 1.1 Duchenne Muscular Dystrophy Drugs Product Introduction
- 1.2 Market Segments
- 1.3 Key Duchenne Muscular Dystrophy Drugs Manufacturers Covered: Ranking by Revenue
- 1.4 Market by Type
- 1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type
- 1.4.2 Development & Drug Target
- 1.4.3 Mechanism of Action (MoA)
- 1.4.4 Route of Administration (RoA)
- 1.4.5 Molecule Type
- 1.5 Market by Application
- 1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Application
- 1.5.2 Hospitals and Clinics
- 1.5.3 Medical Laboratories
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Duchenne Muscular Dystrophy Drugs Market Size, Estimates and Forecasts
- 2.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue 2015-2026
- 2.1.2 Global Duchenne Muscular Dystrophy Drugs Sales 2015-2026
- 2.2 Global Duchenne Muscular Dystrophy Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
- 2.2.1 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
- 2.2.2 Global Duchenne Muscular Dystrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Duchenne Muscular Dystrophy Drugs Competitor Landscape by Players
- 3.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers
- 3.1.1 Duchenne Muscular Dystrophy Drugs Sales by Manufacturers (2015-2020)
- 3.1.2 Duchenne Muscular Dystrophy Drugs Sales Market Share by Manufacturers (2015-2020)
- 3.2 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers
- 3.2.1 Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2015-2020)
- 3.2.2 Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers (2015-2020)
- 3.2.3 Global Duchenne Muscular Dystrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
- 3.2.4 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Drugs Revenue in 2019
- 3.2.5 Global Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.3 Duchenne Muscular Dystrophy Drugs Price by Manufacturers
- 3.4 Duchenne Muscular Dystrophy Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Duchenne Muscular Dystrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Duchenne Muscular Dystrophy Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
- 4.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2015-2020)
- 4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Type (2015-2020)
- 4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Type (2015-2020)
- 4.1.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
- 4.2 Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2021-2026)
- 4.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2021-2026)
- 4.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Type (2021-2026)
- 4.2.3 Duchenne Muscular Dystrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
- 4.3 Global Duchenne Muscular Dystrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
- 5.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2015-2020)
- 5.1.1 Global Duchenne Muscular Dystrophy Drugs Sales by Application (2015-2020)
- 5.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue by Application (2015-2020)
- 5.1.3 Duchenne Muscular Dystrophy Drugs Price by Application (2015-2020)
- 5.2 Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2021-2026)
- 5.2.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2021-2026)
- 5.2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Application (2021-2026)
- 5.2.3 Global Duchenne Muscular Dystrophy Drugs Price Forecast by Application (2021-2026)
6 North America
- 6.1 North America Duchenne Muscular Dystrophy Drugs by Country
- 6.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Country
- 6.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Country
- 6.1.3 U.S.
- 6.1.4 Canada
- 6.2 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
- 6.3 North America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
7 Europe
- 7.1 Europe Duchenne Muscular Dystrophy Drugs by Country
- 7.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Country
- 7.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Country
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 U.K.
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
- 7.3 Europe Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
8 Asia Pacific
- 8.1 Asia Pacific Duchenne Muscular Dystrophy Drugs by Region
- 8.1.1 Asia Pacific Duchenne Muscular Dystrophy Drugs Sales by Region
- 8.1.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Revenue by Region
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 South Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Taiwan
- 8.1.9 Indonesia
- 8.1.10 Thailand
- 8.1.11 Malaysia
- 8.1.12 Philippines
- 8.1.13 Vietnam
- 8.2 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
- 8.3 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
9 Latin America
- 9.1 Latin America Duchenne Muscular Dystrophy Drugs by Country
- 9.1.1 Latin America Duchenne Muscular Dystrophy Drugs Sales by Country
- 9.1.2 Latin America Duchenne Muscular Dystrophy Drugs Revenue by Country
- 9.1.3 Mexico
- 9.1.4 Brazil
- 9.1.5 Argentina
- 9.2 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
- 9.3 Central & South America Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
10 Middle East and Africa
- 10.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs by Country
- 10.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Country
- 10.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Country
- 10.1.3 Turkey
- 10.1.4 Saudi Arabia
- 10.1.5 U.A.E
- 10.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Type
- 10.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Facts & Figures by Application
11 Company Profiles
- 11.1 Akashi Therapeutics Inc
- 11.1.1 Akashi Therapeutics Inc Corporation Information
- 11.1.2 Akashi Therapeutics Inc Description and Business Overview
- 11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.1.5 Akashi Therapeutics Inc Related Developments
- 11.2 Antisense Therapeutics Ltd
- 11.2.1 Antisense Therapeutics Ltd Corporation Information
- 11.2.2 Antisense Therapeutics Ltd Description and Business Overview
- 11.2.3 Antisense Therapeutics Ltd Sales, Revenue and Gross Margin (2015-2020)
- 11.2.4 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Products Offered
- 11.2.5 Antisense Therapeutics Ltd Related Developments
- 11.3 Beech Tree Labs Inc
- 11.3.1 Beech Tree Labs Inc Corporation Information
- 11.3.2 Beech Tree Labs Inc Description and Business Overview
- 11.3.3 Beech Tree Labs Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.3.4 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.3.5 Beech Tree Labs Inc Related Developments
- 11.4 Biogen Inc
- 11.4.1 Biogen Inc Corporation Information
- 11.4.2 Biogen Inc Description and Business Overview
- 11.4.3 Biogen Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.4.4 Biogen Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.4.5 Biogen Inc Related Developments
- 11.5 Bioleaders Corp
- 11.5.1 Bioleaders Corp Corporation Information
- 11.5.2 Bioleaders Corp Description and Business Overview
- 11.5.3 Bioleaders Corp Sales, Revenue and Gross Margin (2015-2020)
- 11.5.4 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Products Offered
- 11.5.5 Bioleaders Corp Related Developments
- 11.6 BioMarin Pharmaceutical Inc
- 11.6.1 BioMarin Pharmaceutical Inc Corporation Information
- 11.6.2 BioMarin Pharmaceutical Inc Description and Business Overview
- 11.6.3 BioMarin Pharmaceutical Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.6.4 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.6.5 BioMarin Pharmaceutical Inc Related Developments
- 11.7 Biophytis SAS
- 11.7.1 Biophytis SAS Corporation Information
- 11.7.2 Biophytis SAS Description and Business Overview
- 11.7.3 Biophytis SAS Sales, Revenue and Gross Margin (2015-2020)
- 11.7.4 Biophytis SAS Duchenne Muscular Dystrophy Drugs Products Offered
- 11.7.5 Biophytis SAS Related Developments
- 11.8 Capricor Therapeutics Inc
- 11.8.1 Capricor Therapeutics Inc Corporation Information
- 11.8.2 Capricor Therapeutics Inc Description and Business Overview
- 11.8.3 Capricor Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.8.4 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.8.5 Capricor Therapeutics Inc Related Developments
- 11.9 Catabasis Pharmaceuticals Inc
- 11.9.1 Catabasis Pharmaceuticals Inc Corporation Information
- 11.9.2 Catabasis Pharmaceuticals Inc Description and Business Overview
- 11.9.3 Catabasis Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.9.4 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.9.5 Catabasis Pharmaceuticals Inc Related Developments
- 11.10 CRISPR Therapeutics
- 11.10.1 CRISPR Therapeutics Corporation Information
- 11.10.2 CRISPR Therapeutics Description and Business Overview
- 11.10.3 CRISPR Therapeutics Sales, Revenue and Gross Margin (2015-2020)
- 11.10.4 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Products Offered
- 11.10.5 CRISPR Therapeutics Related Developments
- 11.1 Akashi Therapeutics Inc
- 11.1.1 Akashi Therapeutics Inc Corporation Information
- 11.1.2 Akashi Therapeutics Inc Description and Business Overview
- 11.1.3 Akashi Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.1.4 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Products Offered
- 11.1.5 Akashi Therapeutics Inc Related Developments
- 11.12 Daiichi Sankyo Co Ltd
- 11.12.1 Daiichi Sankyo Co Ltd Corporation Information
- 11.12.2 Daiichi Sankyo Co Ltd Description and Business Overview
- 11.12.3 Daiichi Sankyo Co Ltd Sales, Revenue and Gross Margin (2015-2020)
- 11.12.4 Daiichi Sankyo Co Ltd Products Offered
- 11.12.5 Daiichi Sankyo Co Ltd Related Developments
- 11.13 Debiopharm International SA
- 11.13.1 Debiopharm International SA Corporation Information
- 11.13.2 Debiopharm International SA Description and Business Overview
- 11.13.3 Debiopharm International SA Sales, Revenue and Gross Margin (2015-2020)
- 11.13.4 Debiopharm International SA Products Offered
- 11.13.5 Debiopharm International SA Related Developments
- 11.14 Editas Medicine Inc
- 11.14.1 Editas Medicine Inc Corporation Information
- 11.14.2 Editas Medicine Inc Description and Business Overview
- 11.14.3 Editas Medicine Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.14.4 Editas Medicine Inc Products Offered
- 11.14.5 Editas Medicine Inc Related Developments
- 11.15 Eloxx Pharmaceuticals Inc
- 11.15.1 Eloxx Pharmaceuticals Inc Corporation Information
- 11.15.2 Eloxx Pharmaceuticals Inc Description and Business Overview
- 11.15.3 Eloxx Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.15.4 Eloxx Pharmaceuticals Inc Products Offered
- 11.15.5 Eloxx Pharmaceuticals Inc Related Developments
- 11.16 F. Hoffmann-La Roche Ltd
- 11.16.1 F. Hoffmann-La Roche Ltd Corporation Information
- 11.16.2 F. Hoffmann-La Roche Ltd Description and Business Overview
- 11.16.3 F. Hoffmann-La Roche Ltd Sales, Revenue and Gross Margin (2015-2020)
- 11.16.4 F. Hoffmann-La Roche Ltd Products Offered
- 11.16.5 F. Hoffmann-La Roche Ltd Related Developments
- 11.17 FibroGen Inc
- 11.17.1 FibroGen Inc Corporation Information
- 11.17.2 FibroGen Inc Description and Business Overview
- 11.17.3 FibroGen Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.17.4 FibroGen Inc Products Offered
- 11.17.5 FibroGen Inc Related Developments
- 11.18 Fulcrum Therapeutics Inc
- 11.18.1 Fulcrum Therapeutics Inc Corporation Information
- 11.18.2 Fulcrum Therapeutics Inc Description and Business Overview
- 11.18.3 Fulcrum Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.18.4 Fulcrum Therapeutics Inc Products Offered
- 11.18.5 Fulcrum Therapeutics Inc Related Developments
- 11.19 Galapagos NV
- 11.19.1 Galapagos NV Corporation Information
- 11.19.2 Galapagos NV Description and Business Overview
- 11.19.3 Galapagos NV Sales, Revenue and Gross Margin (2015-2020)
- 11.19.4 Galapagos NV Products Offered
- 11.19.5 Galapagos NV Related Developments
- 11.20 Genethon SA
- 11.20.1 Genethon SA Corporation Information
- 11.20.2 Genethon SA Description and Business Overview
- 11.20.3 Genethon SA Sales, Revenue and Gross Margin (2015-2020)
- 11.20.4 Genethon SA Products Offered
- 11.20.5 Genethon SA Related Developments
- 11.21 GTx Inc
- 11.21.1 GTx Inc Corporation Information
- 11.21.2 GTx Inc Description and Business Overview
- 11.21.3 GTx Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.21.4 GTx Inc Products Offered
- 11.21.5 GTx Inc Related Developments
- 11.22 Santhera Pharmaceuticals Holding AG
- 11.22.1 Santhera Pharmaceuticals Holding AG Corporation Information
- 11.22.2 Santhera Pharmaceuticals Holding AG Description and Business Overview
- 11.22.3 Santhera Pharmaceuticals Holding AG Sales, Revenue and Gross Margin (2015-2020)
- 11.22.4 Santhera Pharmaceuticals Holding AG Products Offered
- 11.22.5 Santhera Pharmaceuticals Holding AG Related Developments
- 11.23 Sarepta Therapeutics Inc
- 11.23.1 Sarepta Therapeutics Inc Corporation Information
- 11.23.2 Sarepta Therapeutics Inc Description and Business Overview
- 11.23.3 Sarepta Therapeutics Inc Sales, Revenue and Gross Margin (2015-2020)
- 11.23.4 Sarepta Therapeutics Inc Products Offered
- 11.23.5 Sarepta Therapeutics Inc Related Developments
- 11.24 SOM Biotech SL
- 11.24.1 SOM Biotech SL Corporation Information
- 11.24.2 SOM Biotech SL Description and Business Overview
- 11.24.3 SOM Biotech SL Sales, Revenue and Gross Margin (2015-2020)
- 11.24.4 SOM Biotech SL Products Offered
- 11.24.5 SOM Biotech SL Related Developments
- 11.25 Strykagen Corp
- 11.25.1 Strykagen Corp Corporation Information
- 11.25.2 Strykagen Corp Description and Business Overview
- 11.25.3 Strykagen Corp Sales, Revenue and Gross Margin (2015-2020)
- 11.25.4 Strykagen Corp Products Offered
- 11.25.5 Strykagen Corp Related Developments
- 11.26 Summit Therapeutics Plc
- 11.26.1 Summit Therapeutics Plc Corporation Information
- 11.26.2 Summit Therapeutics Plc Description and Business Overview
- 11.26.3 Summit Therapeutics Plc Sales, Revenue and Gross Margin (2015-2020)
- 11.26.4 Summit Therapeutics Plc Products Offered
- 11.26.5 Summit Therapeutics Plc Related Developments
- 11.27 Taiho Pharmaceutical Co Ltd
- 11.27.1 Taiho Pharmaceutical Co Ltd Corporation Information
- 11.27.2 Taiho Pharmaceutical Co Ltd Description and Business Overview
- 11.27.3 Taiho Pharmaceutical Co Ltd Sales, Revenue and Gross Margin (2015-2020)
- 11.27.4 Taiho Pharmaceutical Co Ltd Products Offered
- 11.27.5 Taiho Pharmaceutical Co Ltd Related Developments
- 11.28 Teijin Pharma Ltd
- 11.28.1 Teijin Pharma Ltd Corporation Information
- 11.28.2 Teijin Pharma Ltd Description and Business Overview
- 11.28.3 Teijin Pharma Ltd Sales, Revenue and Gross Margin (2015-2020)
- 11.28.4 Teijin Pharma Ltd Products Offered
- 11.28.5 Teijin Pharma Ltd Related Developments
- 11.29 WAVE Life Sciences Ltd
- 11.29.1 WAVE Life Sciences Ltd Corporation Information
- 11.29.2 WAVE Life Sciences Ltd Description and Business Overview
- 11.29.3 WAVE Life Sciences Ltd Sales, Revenue and Gross Margin (2015-2020)
- 11.29.4 WAVE Life Sciences Ltd Products Offered
- 11.29.5 WAVE Life Sciences Ltd Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
- 12.1 Duchenne Muscular Dystrophy Drugs Market Estimates and Projections by Region
- 12.1.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Regions 2021-2026
- 12.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Forecast by Regions 2021-2026
- 12.2 North America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
- 12.2.1 North America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
- 12.2.2 North America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
- 12.2.3 North America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
- 12.3 Europe Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
- 12.3.1 Europe: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
- 12.3.2 Europe: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
- 12.3.3 Europe: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
- 12.4 Asia Pacific Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
- 12.4.1 Asia Pacific: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
- 12.4.2 Asia Pacific: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
- 12.4.3 Asia Pacific: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Region (2021-2026)
- 12.5 Latin America Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
- 12.5.1 Latin America: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
- 12.5.2 Latin America: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
- 12.5.3 Latin America: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
- 12.6 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Forecast (2021-2026)
- 12.6.1 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Sales Forecast (2021-2026)
- 12.6.2 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Revenue Forecast (2021-2026)
- 12.6.3 Middle East and Africa: Duchenne Muscular Dystrophy Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Porter's Five Forces Analysis
- 13.5 Primary Interviews with Key Duchenne Muscular Dystrophy Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Duchenne Muscular Dystrophy Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Description
Duchenne Muscular Dystrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Duchenne Muscular Dystrophy Drugs market is segmented into
Development & Drug Target
Mechanism of Action (MoA)
Route of Administration (RoA)
Molecule Type
Segment by Application, the Duchenne Muscular Dystrophy Drugs market is segmented into
Hospitals and Clinics
Medical Laboratories
Others
Regional and Country-level Analysis
The Duchenne Muscular Dystrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Duchenne Muscular Dystrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Duchenne Muscular Dystrophy Drugs Market Share Analysis
Duchenne Muscular Dystrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Duchenne Muscular Dystrophy Drugs business, the date to enter into the Duchenne Muscular Dystrophy Drugs market, Duchenne Muscular Dystrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
Akashi Therapeutics Inc
Antisense Therapeutics Ltd
Beech Tree Labs Inc
Biogen Inc
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SAS
Capricor Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
F. Hoffmann-La Roche Ltd
FibroGen Inc
Fulcrum Therapeutics Inc
Galapagos NV
Genethon SA
GTx Inc
Santhera Pharmaceuticals Holding AG
Sarepta Therapeutics Inc
SOM Biotech SL
Strykagen Corp
Summit Therapeutics Plc
Taiho Pharmaceutical Co Ltd
Teijin Pharma Ltd
WAVE Life Sciences Ltd